Read by QxMD icon Read

Drugs of Today

R Ballinger, M Spence, W Chalkley
The Drug Information Association's Annual Meeting is the largest global event which crosses all disciplines involved in the discovery development and life cycle management of healthcare products. The 2016 meeting, its 52nd occurrence, brought experts from regulatory and government agencies, industry, academia and health and patient organizations together to discuss novel therapies in development and how to use these to enhance health and well-being in patient groups, with the hope of increasing knowledge across all areas involved...
August 2016: Drugs of Today
S Lam
Pfizer's Xeljanz (tofacitinib citrate) was the first Janus kinase (JAK) inhibitor to reach the market for rheumatoid arthritis (RA) following its U.S. approval in November 2012, and it has since gained approval in more than 45 countries as a second-line therapy for RA after failure of disease-modifying antirheumatic drugs (DMARDs). This emerging category has heralded an attractive new class of oral treatment options in RA, with a notable opportunity in patients who stop responding to DMARDs, but they are facing a challenging market...
August 2016: Drugs of Today
P D'Souza
During the second quarter of 2016, Cortellis Competitive Intelligence had 1,014 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This was on par with the last quarter (1,011) and a substantial increase on the same quarter for the previous 1 year (659). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestone, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter's pharmaceutical licensing activity...
August 2016: Drugs of Today
E Cruces
During the first quarter of 2016, Cortellis Competitive Intelligence had 1,011 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This was a slight decrease on the last quarter (Q4 2015: 1,075) but a significant increase on the same quarter for the previous year (Q1 2015: 826). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestone, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter's pharmaceutical licensing activity...
August 2016: Drugs of Today
R Andersen, G B E Jemec
Hidradenitis suppurativa (HS) is difficult to treat. Official guidelines have only recently been developed, and suggest that patients should be provided with both adjuvant, medical and surgical therapy. The guidelines are the result of resurgent interest in this disease, in which etiology and pathogenesis are only partially understood at present. Recent research has, however, identified possible targets for specific intervention using biologicals. In addition, classical clinically driven developments of new treatments continue to evolve, leading to several interesting new therapies for HS patients...
August 2016: Drugs of Today
R Navari
Chemotherapy-induced nausea and vomiting (CINV) is a significant clinical issue which affects patients' quality of life as well as treatment decisions. Significant improvements in the control of CINV have occurred in the past 15 years with the introduction of new antiemetic agents: 5-HT3 receptor antagonists, tachykinin NK1 receptor antagonists and olanzapine. Aprepitant was the first NK1 receptor antagonist introduced (2003) for the prevention of CINV in combination with a 5-HT3 receptor antagonist and dexamethasone...
August 2016: Drugs of Today
A Kibble, A Al-Shamahi, K Kuennemann, F Marqués, L Tremosa, P Cole
The theme of the 52nd Annual American Society of Clinical Oncology (ASCO) meeting, 'Collective Wisdom', was intended to represent the importance of consolidating clinical advances with expertise in areas such as health informatics, pathology and economics in order to improve the role of practice providers in delivering cancer patients every component of quality care. As expected, immunotherapy and precision medicine featured heavily in the 2016 program. Gathering 30,000 oncology professionals in Chicago, educational and science sessions gave the attendees the opportunity to discuss and view ground-breaking research...
July 2016: Drugs of Today
A Crescenzo
With the ever-increasing growth of next-generation sequencing literature, how can researchers and clinicians assess clinical actionability and utility and objectively assign confidence to gene variant-phenotype associations? This article presents an informatics solution for clinical interpretation of patient-derived genomic and molecular data containing manually curated scientific evidence supporting gene variant-disease and -drug response phenotypes in somatic cancers. An algorithm for direct evidence scoring will be used to demonstrate the diverse utility of BRAF V600E in treating many common cancers...
July 2016: Drugs of Today
M Baker
If raw DNA sequencing data gave biological insights, there would be no more need for innovation. Interpreting genetic variants at scale continues to challenge evidence-based medicine. Whether using proprietary databases of variant reference content or crowd sourced data, one has to be able to assign some level of confidence to his or her inter¬pretation, define which variants are actionable, and with time speak to the clinical utility of the use of the biomarker.
July 2016: Drugs of Today
B Kiernan
Immuno-oncology (I/O) is changing the way that we approach cancer therapy. As precision medicine comes to the forefront, clinical researchers are beginning to home in on tumors with targeted therapies, focusing on those that have been previously resistant to treatment. This has been accom¬plished with chemical agents in small cancer subsets; how¬ever, immunotherapy seeks to harness the mechanisms of our own immune system to target cancer and its pathways.
July 2016: Drugs of Today
N Gamal, P Andreone
Hepatitis C virus (HCV) infection is an increasing public health concern with an estimated 184 million people infected worldwide and approximately 350,000 deaths yearly from HCV-related complications. There is a compelling medical need for new anti-HCV therapeutic agents that are potent, tolerable, safe, completely oral and with shorter treatment duration. To this end, a plethora of direct-acting antivirals have been developed and regulatory authorities have approved nine new molecules for the treatment of chronic hepatitis C (CHC)...
July 2016: Drugs of Today
S Lam
The 76th American Diabetes Association (ADA) Scientific Sessions took place in New Orleans, Louisiana, USA. The meeting brought together scientists and professionals from a wide range of disciplines in the field of diabetes and provided a platform for networking, allowing experts and researchers to share ideas and learn about the significant advances in diabetes research, treatment and care. Over the course of the 5 days, participants received exclusive access to more than 2,500 original research presentations...
June 2016: Drugs of Today
G Walker, G Croasdell
The 2016 Annual European Congress of Rheumatology, an annual conference organized by the European League Against Rheumatism (EULAR), took place in London, U.K. Over 4,000 abstracts were submitted this year with over 199 sessions and poster tours on offer. The congress has become a major event in the field of rheumatology with participants attending from around the world. The oral sessions, poster displays and lectures cover a broad spectrum of topics, including the latest understanding of disease processes, as well as recent advances in diagnosis and patient care...
June 2016: Drugs of Today
E Hutchinson, M A Pujana, J Arribas
At the Cancer Therapeutic Resistance: Progress and Perspectives conference, in Barcelona, Spain, April 7-8, 2016, researchers, clinicians and students gathered to discuss our current understanding of intrinsic and acquired resistance of tumors to cancer therapies and to explore how to translate strategies to predict risk or overcome resistance to the clinic. The sessions covered a wide range of topics, including cancer omics, molecular classification, clinically relevant tumor models, biomarkers and novel therapeutic targets, and personalized medicine, with talks from many international experts in the field...
June 2016: Drugs of Today
D P S O'Brart
Corneal collagen cross-linking (CXL) with riboflavin and ultraviolet A (UVA) radiation is the first therapeutic modality that appears to arrest the progression of keratoconus and other corneal ectasias. Riboflavin is central to the process, acting as a photosensitizer for the production of oxygen singlets and riboflavin triplets. These free radicals drive the CXL process within the proteins of the corneal stroma, altering its biomechanical properties. Riboflavin also absorbs the majority of the UVA radiation, which is potentially cytotoxic and mutagenic, within the anterior stroma, preventing damage to internal ocular structures, such as the corneal endothelium, lens and retina...
June 2016: Drugs of Today
D M Paton
The starting point for this drug was the growing realization that eosinophils appeared to be associated with a severe form of asthma in which patients were subject to exacerbations of their condition that could not be adequately managed using inhaled and/or oral corticosteroids. Studies of the pathophysiology of eosinophils revealed that they produce many bioactive compounds that contribute to the pathophysiology of a number of diseases including asthma. Interleukin-5 (IL-5) in particular is an important factor in some forms of severe asthma...
June 2016: Drugs of Today
G Croasdell
The 111(th) Annual Meeting of the American Urological Association (AUA) brought together a wide range of researchers in the field of urology to share knowledge and set standards in urological research. The meeting consisted of plenary, podium and moderated poster sessions, in which the latest research and advances in urologic medicine were presented. This report will highlight some of the presentations on therapeutic developments for a range of urological conditions.
May 2016: Drugs of Today
L Hodgkinson
Biotechnology has enabled the development of treatments for many diseases benefiting millions of people. Similar biologics or 'biosimilar' versions of originator biologic medicines are a relatively new category of biologics, usually developed when the originator is protected by patent exclusivity and introduced to healthcare systems as a cheaper option to treat disease. Biosimilars provide value and thus access for new groups of patients because they bring cost savings to the healthcare ecosystem. Generics achieved cost savings of EUR 100 billion in 2014, which allows the system to finance more innovative methods of bringing medicines to patients...
May 2016: Drugs of Today
M D Petit, J Fernández
The 28(th) Drug Information Association (DIA) Annual EuroMeeting took place in Hamburg, Germany, gathering together participants from different industries, organizations, academic research centers, regulatory agencies and health ministries, mainly from the E.U. The conference began with a regulatory Town Hall meeting focusing on the E.U. Medicines Agencies Network strategy to 2020. This was followed by an opening plenary session where the diverse roles of innovation in drug development were discussed. Areas for discussion over the meeting were classified into 14 main themes, and for each session, profession¬als from the pharmaceutical industry, regulatory agencies and health ministries, as well as delegates from patient organizations, presented their considerations for debate...
May 2016: Drugs of Today
R Tibes
Basal cell carcinoma (BCC), although mostly locally confined, is the most common cancer. Most BCCs harbor inactivating mutations in the membrane receptor/gene Ptch, thereby activating the Hedgehog signaling pathway (Hh) via the essential signaling molecule Smoothened (SMO). Novel small-molecule inhibitors or antagonists of SMO have shown excellent response rates in patients with locally advanced, unresectable and metastatic BCC in roughly 35-60% of patients, with disease control rates and clinical benefit being even higher...
May 2016: Drugs of Today
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"